omica.ai
Omica turns fragmented clinical records and biospecimens into curated, de-identified datasets that enable biomedical AI and translational research. The company ingests multimodal patient data — including clinical notes, pathology, imaging, and genomics — using automated ETL pipelines combined with clinical oversight to standardize, validate, and produce longitudinal outputs. Omica operates a data platform (Atlas) for cohort discovery, model validation, and export of structured training datasets, positioning itself as a B2B data infrastructure provider for life science R&D. It partners directly with hospitals and labs, focusing on underrepresented populations in Latin America, and supports customers in pharma and AI diagnostics. Omica’s stack emphasizes secure data de-identification, scalable data engineering, and clinical QA for downstream model training and real-world evidence applications.
omica.ai
Omica turns fragmented clinical records and biospecimens into curated, de-identified datasets that enable biomedical AI and translational research. The company ingests multimodal patient data — including clinical notes, pathology, imaging, and genomics — using automated ETL pipelines combined with clinical oversight to standardize, validate, and produce longitudinal outputs. Omica operates a data platform (Atlas) for cohort discovery, model validation, and export of structured training datasets, positioning itself as a B2B data infrastructure provider for life science R&D. It partners directly with hospitals and labs, focusing on underrepresented populations in Latin America, and supports customers in pharma and AI diagnostics. Omica’s stack emphasizes secure data de-identification, scalable data engineering, and clinical QA for downstream model training and real-world evidence applications.
TL;DR
What they do: Build multimodal, de-identified AI-ready clinical and multiomics datasets (digital biobank) for research and model development
Geographic focus: Underrepresented populations in Latin America; headquartered in Mexico City
Founded: 2021
Business model: B2B data infrastructure partnering with hospitals, labs, and pharma/AI diagnostics customers
Notable tech/product: Data platform (Atlas / omicaMD) for cohort discovery, de-identification, validation and dataset export
Company Overview
Problem Domain
Fragmented clinical records and biorepositories that are not standardized or de-identified for AI and translational research.
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
1000000
Public profiles list investors including Brandon White, Plug and Play, Caffeinated Capital, Axial VC and others
Investor Signal
“Has pre-seed/backing from angel and early-stage investors including named individuals and firms”